

Rong Fan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5230378/publications.pdf>

Version: 2024-02-01

35
papers

756
citations

758635

12
h-index

552369

26
g-index

37
all docs

37
docs citations

37
times ranked

966
citing authors

#	ARTICLE	IF	CITATIONS
1	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	1.8	158
2	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. <i>Gut</i> , 2016, 65, 313-320.	6.1	112
3	Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 719-727.e7.	2.4	72
4	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study. <i>Hepatology</i> , 2014, 59, 1283-1292.	3.6	69
5	Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. <i>Cell Research</i> , 2021, 31, 589-592.	5.7	59
6	Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2020, 222, 611-618.	1.9	50
7	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. <i>Journal of Hepatology</i> , 2016, 65, 674-682.	1.8	36
8	Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 692-700.	1.9	22
9	The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients. <i>Clinical Cancer Research</i> , 2021, 27, 3772-3783.	3.2	21
10	Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 196-204.e8.	2.4	18
11	Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. <i>Scientific Reports</i> , 2015, 5, 17123.	1.6	14
12	Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 329-338.	1.9	14
13	A hepatitis B-free generation in China: from dream to reality. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1103-1105.	4.6	13
14	Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients. <i>Hepatology Research</i> , 2018, 48, 134-143.	1.8	12
15	Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy. <i>Journal of Infectious Diseases</i> , 2022, 226, 881-890.	1.9	12
16	Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment. <i>Clinical Immunology</i> , 2019, 198, 31-38.	1.4	10
17	Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients. <i>Antiviral Research</i> , 2021, 189, 105037.	1.9	10
18	Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2016, 33, 519-531.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2019, 220, 1469-1476.	1.9	7
20	Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non- ϵ cirrhotic HBeAg- ϵ positive chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1121-1129.	1.0	7
21	Hepatitis B Core-Related Antigen is a Biomarker for off-Treatment Relapse After Long-Term Nucleos(t)ide Analog Therapy in Patients with Chronic Hepatitis B. <i>International Journal of General Medicine</i> , 2021, Volume 14, 4967-4976.	0.8	6
22	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir- ϵ treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1206-1213.	2.5	5
23	Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B. <i>BMC Infectious Diseases</i> , 2019, 19, 640.	1.3	4
24	Reply to: ϵ External validation of aMAP risk score in patients with chronic hepatitis C genotype 4 and cirrhosis who achieved SVR following DAAs ϵ . <i>Journal of Hepatology</i> , 2021, 74, 996-997.	1.8	3
25	Sexual Dysfunction in Patients with Chronic Hepatitis B: Prevalence and Risk Factors. <i>Journal of Sexual Medicine</i> , 2022, 19, 207-215.	0.3	3
26	Real- ϵ life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients. <i>Journal of Medical Virology</i> , 2022, 94, 5465-5474.	2.5	3
27	Prevalence of Dual-Positivity for Both Hepatitis B e Antigen and Hepatitis B e Antibody Among Hospitalized Patients with Chronic Hepatitis B Virus Infection. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5759-5770.	0.8	2
28	An individualized cirrhosis screening strategy might be more cost-effective in the general population. <i>Journal of Hepatology</i> , 2022, 77, 1728-1729.	1.8	2
29	Combination Therapy With Tenofovir and Peginterferon May Not Be Translated Into Current Clinical Practice. <i>Gastroenterology</i> , 2016, 150, 1253-1254.	0.6	1
30	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2147-2148.	2.4	1
31	Poor response to inactivated SARS-CoV-2 vaccine in patients with chronic liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	1
32	Letter to the Editor: Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, , .	1.8	1
33	Stopping oral antiviral treatment to cure chronic hepatitis B, is it in sight?. <i>Hepatology International</i> , 2020, 14, 302-304.	1.9	0
34	Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti- ϵ viral therapy ϵ authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 724-725.	1.9	0
35	Early detection of hepatocellular carcinoma using cfDNA signatures from cirrhotic patients with nodules.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4113-4113.	0.8	0